Aristotle Capital Boston Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Northern Oil and Gas
NOG
|
+$12.9M |
| 2 |
LKQ Corp
LKQ
|
+$5.23M |
| 3 |
MODV
ModivCare
MODV
|
+$3.07M |
| 4 |
Cerence
CRNC
|
+$2.05M |
| 5 |
Rogers Corp
ROG
|
+$1.62M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SP
SP Plus Corporation
SP
|
+$20.9M |
| 2 |
Huron Consulting
HURN
|
+$20.4M |
| 3 |
MACOM Technology Solutions
MTSI
|
+$16M |
| 4 |
Patterson-UTI
PTEN
|
+$10.6M |
| 5 |
Coherus Oncology
CHRS
|
+$8.76M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Industrials | 25.41% |
| 2 | Technology | 18.57% |
| 3 | Healthcare | 16% |
| 4 | Financials | 13.89% |
| 5 | Consumer Discretionary | 8.58% |
Similar funds
Aristotle Capital Boston's Q4 2023 Portfolio in Review
As of Q4 2023, Aristotle Capital Boston held 132 positions worth $3.27B, up 5.5% from $3.1B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
Aristotle Capital Boston withdrew a net $151M in Q4 2023, closing 1 position and reducing 93 holdings. Its most notable exit was Coherus Oncology, an estimated $8.76M position sold in full.
By sector, the portfolio is most concentrated in Industrials at 25% of assets, down from 26% a quarter earlier, followed by Technology and Healthcare.
Against the trend, Aristotle Capital Boston opened a new position in Northern Oil and Gas worth $12.6M.
- Aristotle Capital Boston's largest Q4 2023 buy was Northern Oil and Gas: 339,979 shares worth $12.6M.
- Aristotle Capital Boston added most to ModivCare in Q4 2023, an estimated $3.07M increase.
- Aristotle Capital Boston's biggest Q4 2023 reduction was SP Plus Corporation, cutting an estimated $20.9M.
- Aristotle Capital Boston fully exited Coherus Oncology in Q4 2023, selling an estimated $8.76M.
- Aristotle Capital Boston's ten largest holdings make up 19% of its $3.27B portfolio in Q4 2023.
- Aristotle Capital Boston opened 3 new positions and closed 1 in Q4 2023.
- Aristotle Capital Boston's portfolio value rose 5.5% quarter-over-quarter to $3.27B.
Based on Aristotle Capital Boston's 13F filing for Q4 2023, filed 14 Feb 2024.